Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine is under clinical development by FluGen and currently in Phase I for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H3N2 Subtype Infections have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine overview

Influenza vaccine is under development for the prevention of influenza A strain H3N2 infections. It is administered through intranasal route. The drug candidate is a monovalent vaccine derived from Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR strain.

FluGen overview

FluGen is a developer of influenza vaccines and therapies. The company discovers, develops, and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen’s redeeflu provides better efficacy against seasonal and pandemic influenza and protection against future pandemic strains. Its redeeflu viruses infect cells, express the entire spectrum of influenza RNA and proteins but cannot produce any infectious virus particles. The company conducts research and development activities with various research facilities. FluGen is headquartered in Madison, Wisconsin, the US.

For a complete picture of Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.